N-(3,3-dimethylbutyl)-4-(2-methylthiazol-4-yl)benzene sulfonamide | 1589818-82-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,3-dimethylbutyl)-4-(2-methylthiazol-4-yl)benzene sulfonamide
• 英文别名: N-(3,3-dimethylbutyl)-4-(2-methyl-1,3-thiazol-4-yl)benzenesulfonamide
• CAS: 1589818-82-5
• 化学式: C₁₆H₂₂N₂O₂S₂
• 分子量: 338.495
• InChiKey: RVKZPAWAVNVGGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(2-甲基-1,3-噻唑-4-基)苯磺酰氯 、 3,3-二甲基丁胺 在 N-甲基吗啉 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以44%的产率得到N-(3,3-dimethylbutyl)-4-(2-methylthiazol-4-yl)benzene sulfonamide
  参考文献：
  名称：

  Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches

  摘要：

  Tuberculosis remains a major cause of mortality and morbidity, killing each year more than one million people. Although the combined use of first line antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) is efficient to treat most patients, the rapid emergence of multidrug resistant strains of Mycobacterium tuberculosis stresses the need for alternative therapies. Mycobacterial transcriptional repressor EthR is a key player in the control of second-line drugs bioactivation such as ethionamide and has been shown to impair the sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. As a way to identify new potent ligands of this protein, we have developed fragment-based approaches. In the current study, we combined surface plasmon resonance assay, X-ray crystallography, and ligand efficiency driven design for the rapid discovery and optimization of new chemotypes of EthR ligands starting from a fragment. The design, synthesis, and in vitro and ex vivo activities of these compounds will be discussed.

  DOI：

  10.1021/jm500422b

文献信息

• COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS
  申请人：UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2

  公开号：US20150225388A1

  公开（公告）日：2015-08-13

  The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO 2 ; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections. The present invention also concerns pharmaceutical compositions comprising, as the active ingredient, at least one of the abovementioned compounds and optionally an antibiotic activatable via the EthA pathway

  本发明涉及通式（I）的化合物： 其中Y和Z从CH和N中选择；T从CO或SO2中选择；n为1到3；R1代表选择的一种基团，例如从C1-C3烷基链中未取代或取代的氟，未取代或取代的环状，氰基，偶氮基，烷氧基和苯基；R从偶氮基，氰基，炔烃基和2-苯并噻唑基以及一个可选择取代的具有五个顶点的芳香杂环中选择；以及其在治疗细菌和分枝杆菌感染，如肺结核、麻风和非典型分枝杆菌感染中的用途。本发明还涉及包含上述化合物中至少一种和可选通过EthA途径激活的抗生素作为活性成分的药物组合物。
• COMPOSES UTILISABLES DANS LE TRAITEMENT DES INFECTIONS MYCOBACTERIENNES
  申请人：Université de Droit et de la Santé de Lille 2

  公开号：EP2900638A1

  公开（公告）日：2015-08-05
• US9920042B2
  申请人：——

  公开号：US9920042B2

  公开（公告）日：2018-03-20
• Ligand Efficiency Driven Design of New Inhibitors of <i>Mycobacterium tuberculosis</i> Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
  作者：Baptiste Villemagne、Marion Flipo、Nicolas Blondiaux、Céline Crauste、Sandra Malaquin、Florence Leroux、Catherine Piveteau、Vincent Villeret、Priscille Brodin、Bruno O. Villoutreix、Olivier Sperandio、Sameh H. Soror、Alexandre Wohlkönig、René Wintjens、Benoit Deprez、Alain R. Baulard、Nicolas Willand

  DOI：10.1021/jm500422b

  日期：2014.6.12

  Tuberculosis remains a major cause of mortality and morbidity, killing each year more than one million people. Although the combined use of first line antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) is efficient to treat most patients, the rapid emergence of multidrug resistant strains of Mycobacterium tuberculosis stresses the need for alternative therapies. Mycobacterial transcriptional repressor EthR is a key player in the control of second-line drugs bioactivation such as ethionamide and has been shown to impair the sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. As a way to identify new potent ligands of this protein, we have developed fragment-based approaches. In the current study, we combined surface plasmon resonance assay, X-ray crystallography, and ligand efficiency driven design for the rapid discovery and optimization of new chemotypes of EthR ligands starting from a fragment. The design, synthesis, and in vitro and ex vivo activities of these compounds will be discussed.